Constitutive Androstane Receptor-Mediated Upregulation of ATP-Driven Xenobiotic Efflux Transporters at the Blood-Brain Barrier

Xueqian Wang, Destiny B. Sykes and David S. Miller

Laboratory of Toxicology and Pharmacology
National Institute of Environmental Health Sciences, National Institute of Health, Research Triangle Park, North Carolina 27709
Running Title: CAR Regulation of ABC Transporters in Brain Capillaries

Corresponding Author: David S. Miller, Ph.D.
Laboratory of Toxicology and Pharmacology
National Institute of Environmental Health Sciences
National Institutes of Health
Research Triangle Park, NC 27709, USA
Phone: 919-541-3235; Fax: 919-541-5737
Email: miller@niehs.nih.gov

Number of text pages: 28
Number of tables: 0
Number of figures: 10
Number of references: 35
Number of words in Abstract: 170
Number of words in Introduction: 426
Number of words in Discussion: 961

Abbreviations: CNS, central nervous system; CAR, constitutive androstane receptor; PXR, pregnane X receptor; PCN, pregnenolone 16α-carbonitrile; TCPOBOP, 1,4-Bis-[2-(3,5-dichloropyridyloxy)]benzene; NBD-CSA, [N-є(4-nitrobenzofurazan-7-yl)-D-Lys8]-cyclosporine A; Mrp2, multidrug resistance associated protein 2; BCRP, breast cancer resistance protein; OA, okadaic acid; PB, phenobarbital; LTC4, leukotriene C4; FTC, fumitremorgin C; PP2A, protein phosphatase 2A
Abstract

ATP-driven efflux transporters at the blood-brain barrier both protect against neurotoxicants and limit drug delivery to the brain. In other barrier and excretory tissues, efflux transporter expression is regulated by certain ligand activated nuclear receptors. Here we identified CAR as a positive regulator of P-glycoprotein, Mrp2 and BCRP expression in rat and mouse brain capillaries. Exposing rat brain capillaries to the CAR activator, PB, increased the transport activity and protein expression (Western blots) of P-glycoprotein, Mrp2 and BCRP. Induction of transport was abolished by the protein phosphatase 2A inhibitor, OA. Similar effects on transporter activity and expression were found when mouse brain capillaries were exposed to the mouse-specific CAR ligand, TCPOBOP. In brain capillaries from CAR-null mice, TCPOBOP did not increase transporter activity. Finally, dosing mice with 0.33mg/kg TCPOBOP or rats with 80 mg/kg PB increased P-glycoprotein-, Mrp2- and BCRP-mediated transport and protein expression in brain capillaries assayed ex vivo. Thus, CAR activation selectively tightens the blood-brain barrier by increasing transport activity and protein expression of three xenobiotic efflux pumps.
Introduction

The brain capillary endothelium, which comprises the blood-brain barrier, is a major obstacle to the delivery of therapeutic drugs to the brain. In addition to low permeability tight junctions between cells, brain capillary endothelial cells express ATP driven drug efflux pumps (ABC transporters) at the luminal plasma membrane, e.g., P-glycoprotein, BCRP, Mrp2 and Mrp4 (Abbott et al.). These both limit CNS accumulation of small drugs (P-glycoprotein, BCRP, Mrp4) and facilitate excretion of drug metabolites and waste products of CNS metabolism (Mrp2). Certainly for P-glycoprotein (Miller et al., 2008) and likely for BCRP, increased transporter expression selectively tightens the barrier to drugs that are substrates and reduced transporter expression selectively loosens the barrier.

In hepatocytes and other barrier and excretory tissues, PXR and CAR, both former orphan nuclear receptors, coordinately upregulate expression of phase I and phase II drug metabolism as well as increase excretory transport mediated by ABC transporters (Wang and Negishi, 2003; Xu et al., 2005). This upregulation occurs in response to receptor ligands that are endogenous metabolites (e.g., bile acids) and xenobiotics (e.g., therapeutic drugs, dietary constituents and environmental toxicants) (Stanley et al., 2006). Recent studies with isolated rodent brain capillaries and brain capillary endothelial cells show transcriptional upregulation of P-glycoprotein, BCRP and Mrp2 by ligands that activate PXR (Bauer et al., 2004; Bauer et al., 2008; Bauer et al., 2006). Importantly, dosing “humanized” transgenic mice with the hPXR ligand, rifampin, increased P-glycoprotein expression at the blood-brain barrier and substantially reduced CNS efficacy of the P-glycoprotein substrate, methadone (Bauer et al., 2006). Thus, increased expression of P-glycoprotein at the blood-brain barrier influenced drug CNS pharmacodynamics.
Although there are clearly ligands that activate only one of the two receptors, the list of known PXR and CAR ligands do overlap to some extent (Moore et al., 2003). The same could be said about target genes and PXR and CAR promoter elements (Wei et al., 2002; Xie et al., 2000). As with PXR, CAR regulation of transporter expression is less well studied than induction of xenobiotic metabolizing enzymes. Recent reports suggest increases in ABC transporter mRNA in response to CAR ligands (Burk et al., 2005; Jigorel et al., 2006; Kast et al., 2002), but to date there are few reports showing increased transporter protein expression (Lombardo et al., 2008; Xiong et al., 2002) and none showing increased transporter activity. We report here that CAR mRNA and protein are expressed in isolated rat and mouse brain capillaries and that CAR activation increases expression and transport activity of blood-brain barrier P-glycoprotein, BCRP and Mrp2 in vitro and in vivo.
Materials and Methods

**Materials.** Rabbit polyclonal CAR antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA), mouse polyclonal P-glycoprotein antibody was from Covance, and antibodies against Mrp2, and BCRP were from Alexis Biochemicals (San Diego, CA). NBD-CSA was custom-synthesized (Schramm et al., 1995), and BODIPY-prazosin was purchased from Invitrogen (Eugene, OR). PSC833 was kindly provided by Novartis. MK571 was obtained from Cayman Chemical (Ann Arbor, MI). KO143 (Allen et al., 2002) was a kind gift from Dr. Alfred H. Schinkel, of the Netherlands Cancer Institute (Amsterdam, The Netherlands). Sodium PB, PCN, TCPOBOP, OA, LTC₄, wortmannin, Texas red (sulforhodamine 101 free acid), mouse monoclonal β-actin antibody, FTC, Ficoll and all other chemicals were obtained from Sigma-Aldrich. All reagents were of analytical grade or the best available pharmaceutical grade.

**Animals.** All experiments were performed in compliance with NIH animal care and use guidelines and approved by the Animal Care and Use Committee of NIEHS. Male retired breeder Sprague-Dawley rats (6-9 months, Taconic, Germantown, NY), male C3H mice (Charles River, Wilmington, MA) and CAR knockout mice (kindly provided by Dr. Masahiko Negishi, NIEHS/NIH; bred on C3H background) were housed in temperature-controlled rooms under a 12-h light/12-h dark cycle and were given *ad libitum* access to food and water. At the time of use, mice were 10 weeks old, weighing 24.8±1.5g. Animals were euthanized by CO₂ inhalation followed by decapitation. For *in vivo* dosing of mice, PCN or TCPOBOP dissolved in corn oil (Sigma) was given once a day for 2 days by *i.p.* injection at a dose of 50mg/kg (PCN) and 0.33 mg/kg (TCPOBP). Controls received the same volume of corn oil. On day 3, brain capillaries were prepared and immediately used for transport experiments and capillary membrane isolation for subsequent assay by Western blotting. For *in vivo* dosing of rats, PB dissolved in normal
saline solution was given once a day for 4 days by i.p. injection at a dose of 80mg/kg. Controls received the same volume of saline solution. On day 5, brain capillaries were prepared and immediately used for transport experiments and capillary membrane isolation for subsequent assay by Western blotting.

**Capillary Isolation.** The detailed procedures for capillary isolation were described previously (Hartz et al., 2004; Miller et al., 2000). Briefly, white matter, meninges, midbrain, choroid plexus, blood vessels and olfactory lobes were removed from the brains under a dissecting microscope and brain tissue homogenized. Tissue was kept in cold PBS (2.7 mM KCl, 1.2 mM KH₂PO₄, 136.9 mM NaCl, 8.1 mM Na₂HPO₄, 1 mM CaCl₂, 0.5 mM MgCl₂, 5 mM D-glucose and 1mM sodium pyruvate) throughout the isolation procedure. An aliquot of 30% Ficoll was added to an equal volume of brain homogenate and capillaries were separated from the parenchyma by centrifuging at 5,800g for 20 min. Capillary pellets were washed with 1% BSA in PBS and passed through a syringe column filled with glass beads. Capillaries bound to the glass beads were released by gentle agitation, then washed with PBS and used immediately for experiments.

**CAR Immunostaining.** Brain capillaries were fixed in 3% paraformaldehyde/ 0.25% glutaraldehyde in PBS for 10 min, permeabilized with 0.5% Triton X-100 in PBS for 30 min and washed with PBS. After blocking with 1% BSA in PBS for 30 min, capillaries were incubated with rabbit anti-CAR antibody (1:200) in PBS with 1% BSA at 37°C for 60 min, washed with PBS with 1% BSA, and then incubated with Alexa-488 conjugated secondary antibody (1:500) in PBS with 1% BSA at 37°C for 60 min. After further washing in PBS with 1% BSA, tissue was transferred to chambers for confocal microscopy. Negative controls were treated identically except they were not exposed to primary antibody.
**Transport.** Confocal microscopy-based transport assays with isolated rat and mouse brain capillaries have been described previously (Hartz et al., 2004). All experiments were carried out at room temperature in coverslip-bottomed imaging chambers filled with PBS. Protocols for specific experiments are described in respective figure legends. In general, brain capillaries were exposed for 1-3 h to CAR and PXR activators without or with additional inhibitors. Fluorescent substrates NBD-CSA for P-glycoprotein (Hartz et al., 2004; Miller et al., 2000), Texas red for Mrp2 (Bauer et al., 2008) and BODIPY-prazosin for BCRP (Shukla et al., 2009) were added and luminal substrate accumulation was assessed 1 h later. In some experiments specific inhibitors of transport were included in the incubation medium. To acquire images, the chamber containing the capillaries was mounted on the stage of a Zeiss Model 510 inverted confocal laser scanning microscope and imaged through a 40× water-immersion objective (numeric aperture=1.2) using a 488-nm (for NBD-CSA or BODIPY-prazosin) or 543-nm (for Texas red) laser line for excitation. Images were saved to disk and luminal fluorescence was quantitated by Image J software as before (Miller et al., 2000). Data shown are for a single experiment that is representative of 3-5 replicates.

**Western Blots.** Membranes were isolated from control and ligand or activator-exposed capillaries as described previously (Bauer et al., 2006; Hartz et al., 2004). Membrane protein was assayed by the Bradford method. An aliquot of the membrane protein was mixed with NuPAGE 4×sample buffer (Invitrogen, Carlsbad, CA), loaded onto 4-12% Bis-Tris NuPAGE gel, electrophoresed, and then transferred to an Immobilon-FL membrane (Millipore, Bedford, MA). The membrane was blocked with Odyssey Blocking Buffer (Li-Cor Biosciences, Lincoln, NE) at room temperature for 1 h, and then immunoblotted overnight with antibodies against P-glycoprotein, Mrp2, or BCRP, an Odyssey Infrared Imaging System (Li-Cor Biosciences,
Lincoln, NE). The membrane was stained with corresponding goat anti-rabbit or goat anti-mouse fluorescence dyes IRDye 680 (or IRDye 800) in PBS with 0.1% Tween 20 at room temperature for 45 min and then imaged using an Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE). β-actin (42 kD) (1:2000) was used as a loading control; the corresponding secondary antibody was IREDye goat anti-mouse antibody (1:15,000). NewBlot PVDF Stripping Buffer (5×, Li-Cor Biosciences) was used to strip the membranes when needed. The membrane was scanned to ensure complete antibody removal before reprobing the membrane.

**Statistical Analyses.** Data are expressed as mean ± SEM. Statistical analyses of differences between groups was by one-way ANOVA (Newman-Keuls multiple comparison test) using Prism 4.0 software. Differences between two means were considered significant when P<0.05.
Results

mRNA for CAR has been detected in human brain capillaries (Dauchy et al., 2008), but not in the rat (Akanuma et al., 2008). We show here by three criteria that CAR mRNA and protein are present in freshly isolated brain capillaries from rat and mouse. First, RT-PCR assays produced specific CAR amplicons in rat and mouse brain capillary RNA (Fig. 1A). The PCR products were confirmed by direct sequencing to be identical to the rat and mouse CAR genes. Second, Western blots of total capillary lysates yielded a single, clear protein band (~60kD) when an antibody against CAR was used. CAR protein was also detected in membranes isolated from rat and mouse brain capillaries (Fig. 1B). A previous report had localized CAR to the plasma membrane in mouse liver (Koike et al., 2005). The physiological significance of membrane-localized CAR is not yet clear. Third, immunocytochemical studies demonstrated that CAR protein was extensively distributed in the cytoplasm and the nucleus of rat brain capillary endothelial cells (Fig. 1C). Staining of capillary plasma membranes was also visible, consistent with our capillary membrane Western blots.

Having established that CAR is expressed in brain capillaries from rat and mouse, we examined the ability that CAR alters the transport activity and protein expression of three ABC transporters: P-glycoprotein, Mrp2 and BCRP, previously shown to be CAR targets in hepatocytes (Jigorel et al., 2006; Kast et al., 2002). The transport activity assay we employed utilized freshly isolated brain capillaries, fluorescent transport substrates, confocal microscopy and quantitative image analysis to measure substrate accumulation in capillary lumens (vascular space). Previous studies validated NBD-CSA and sulforhodamine 101 free acid (Texas red) as specific substrates for P-glycoprotein and Mrp2, respectively (Bauer et al., 2008; Hartz et al., 2004; Miller et al., 2000). A recent report indicates that BODIPY-prazosin can serve the same
function for BCRP (Shukla et al., 2009); we have confirmed this in preliminary experiments, which show inhibition of luminal BODIPY-prazosin accumulation by the metabolic inhibitor, NaCN and by the specific BCRP inhibitors, FTC and Ko143, but not by PSC833 (inhibits P-glycoprotein) or LTC4 (inhibits Mrps; see Supplemental Figure). Representative confocal images of rat brain capillaries incubated to steady state (60 min) with the three fluorescent substrates are shown in Fig. 2. In each control image, fluorescence is concentrated in the luminal space and, for each, luminal fluorescence was substantially reduced when capillaries were exposed to a specific transport inhibitor, i.e., PSC833 for P-glycoprotein, LTC4 for Mrp2 and FTC for BCRP. Measurements of the effects of these transport inhibitors are shown in each panel of Fig. 2. In every case, inhibitors reduced basal (control) accumulation of respective substrates by at least 50%. Previous studies indicate that residual luminal substrate accumulation is non-specific, likely representing diffusive entry plus binding to cellular elements (Bauer et al., 2008; Hartz et al., 2004).

Figure 2 also shows that exposing rat brain capillaries to PB (1 mM) significantly increased luminal accumulation of NBD-CSA, Texas red and BODIPY-prazosin. PB-induced increases in transport occurred over a period of several hours with maximal stimulation of transport occurring at 3 h for all three substrates (Fig. 3A-C). Note that in these experiments luminal substrate accumulation in control capillaries did not change over the 4 h time course, confirming the metabolic stability of the isolated capillary preparation.

CAR activation involves the recruitment of cytoplasmic CAR retention protein and dephosphorylation by PP2A (Timsit and Negishi, 2007; Yoshinari et al., 2003). Consistent with a role for PP2A in CAR activation, 10 nM OA inhibited PB upregulation of cytochrome P450 2B genes in rodent liver (Kawamoto et al., 1999). With rat brain capillaries, we found that
pretreatment with 2 nM OA abolished the PB-induced increase in transport activity for all three transporters; OA, by itself, had no effect on transport (Fig. 3D-F).

In the remaining experiments, we exposed capillaries to CAR PB or TCPOBOP for 3 h and then assayed steady state substrate accumulation after an additional h incubation with ligand plus fluorescent substrate. For each treatment, we calculated specific transport as the difference between accumulation without and with transport inhibitor (PSC833 for P-glycoprotein, LTC₄ for Mrp2 and FTC for BCRP). With rat capillaries, increases in specific transport caused by exposure to 1 mM PB averaged 76 ± 5% (5 preparations), 183 ± 36% (3 preparations) and 82 ± 3% (3 preparations) for P-glycoprotein, Mrp2 and BCRP, respectively (Fig. 4A-C). For all three transporters, increases in activity were abolished by either actinomycin D or cyclohexamide, indicating dependence on transcription and translation (Fig. 5). Consistent with increased translation, Western blots showed that PB exposure increased protein expression for all three transporters (Fig. 4D). Quantitation of bands from 4 experiments indicated that normalized band density for P-glycoprotein, Mrp2 and BCRP had increased by 58 ± 10%, 38 ± 5% and 40 ± 5%, respectively (all significantly increased by paired t-test, P<0.05).

Mice provide two advantages for the study of CAR regulation of ABC transporters: TCPOBOP is a specific and potent CAR ligand (Timsit and Negishi, 2007) and CAR-null mice have been produced (Ueda et al., 2002). In mouse brain capillaries, transport activity for P-glycoprotein, Mrp2 and BCRP increased after exposure to 50-250 nM TCPOBOP (Fig. 6A,C,E). As shown above for PB induction of transport in rat brain capillaries, 10 nM OA blocked these effects of TCPOBOP in mouse capillaries (Fig. 6B,D,F).

To further confirm the role of CAR in the modulation of ABC transporter activity and expression, parallel experiments were conducted in brain capillaries isolated from CAR-null
mice. These knockout mice were bred on a C3H background (Jackson et al., 2006; Ueda et al., 2002), so the appropriate wild-type controls are the animals used in the experiments shown in Fig. 6. Exposing capillaries from CAR-null mice to 250 nM TCPOBOP did not increase transport mediated by P-glycoprotein, Mrp2 or BCRP (Fig. 7). Consistent with previous experiments in rat and mouse (Bauer et al., 2004; Bauer et al., 2006), PCN, a specific ligand for rodent PXR, significantly increased transport on P-glycoprotein and Mrp2. Transport on BCRP was also increased by PCN exposure, suggesting for the first time that BCRP is a PXR target gene in brain capillaries. This finding that is in agreement with results from primary human hepatocytes (Jigorel et al., 2006) and from in vivo dosing experiments with wild-type and PXR-null mice (Anapolsky et al., 2006).

Taken together, these in vitro experiments with rat and mouse brain capillaries show that the xenobiotics, PB and TCPOBOP, activate the nuclear receptor, CAR, leading to increased transport activity and protein expression for three ABC transporters: P-glycoprotein, Mrp2 and BCRP. To determine the effect of CAR ligand exposure on blood-brain barrier transporter activity and expression in vivo, we dosed mice with PCN (50 mg/kg) or TCPOBOP (0.33 mg/kg) for two days by intraperitoneal injection and then isolated brain capillaries to determine transport activity and transporter expression. Livers were also collected and liver membranes prepared as a positive control. The dose levels were chosen based on the published data showing significant induction by CAR or PXR (Bauer et al., 2004; Zelko et al., 2001). Figure 8A-C shows that dosing mice with PCN or TCPOBOP significantly increased the transport activity of P-glycoprotein, Mrp2 and BCRP in brain capillaries. Pooled results from 4-5 separate preparations showed that specific transport on P-glycoprotein, Mrp2 and BCRP increased on average by 93%, 149% and 120%, respectively (Fig. 8D-F). Consistent with increased transporter expression,
Western blots showed that TCPOBOP dosing increased immunoreactivity for all three transport proteins in membranes isolated from both brain capillaries and liver (Fig. 9). Quantitation of bands from 3 dosing experiments indicated that normalized band density for P-glycoprotein, Mrp2 and BCRP had increased by 57 ± 3%, 30 ± 3% and 37 ± 6%, respectively (all significantly increased by paired t-test, P<0.01 for P-glycoprotein, P<0.05 for Mrp2 and BCRP).

In a second set of in vivo experiments, we dosed rats by intraperitoneal injection with 80 mg/kg PB for 4 days and isolated brain capillaries to determine transport activity and transporter expression. Figure 10 shows that, as with TCPOBOP in mice, PB dosing in rats increased the transport activity of P-glycoprotein, Mrp2 and BCRP in brain capillaries and increased protein expression of the transporters in brain capillary membranes and in liver membranes.
Discussion

We previously demonstrated upregulation of blood-brain barrier P-glycoprotein and Mrp2 by ligands that activate the nuclear receptor, PXR (Bauer et al., 2004; Bauer et al., 2008; Bauer et al., 2006; Zelko et al., 2001). The present experiments suggest that blood-brain barrier BCRP is also a PXR target, a finding that is in agreement with results from primary human hepatocytes (Jigorel et al., 2006) and from in vivo dosing experiments with wild-type and PXR-null mice (Anapolsky et al., 2006). The present results for rodent brain capillaries identify another ligand-activated receptor through which xenobiotics and endogenous metabolites can influence blood-brain barrier transport function. By three distinguishing criteria, we established for the first time that the ligand-activated nuclear receptor, CAR, is an inducer of expression and transport activity of multiple ABC transporters at the blood-brain barrier.

First, we demonstrated expression of CAR at the mRNA and protein levels in extracts from freshly isolated rat and mouse brain capillaries and by immunostaining intact rat brain capillaries. Previously, CAR expression had been detected in a number of barrier and excretory tissues (Lamba et al., 2004; Nannelli et al., 2008), but attempts to establish expression of this receptor at the blood-brain barrier were inconclusive. That is, Akanuma et al. (2008) were unable to detect CAR and PXR mRNA in a rat brain capillary fraction and in a rat brain capillary endothelial cell line. However, Dauchy et al. found low but detectable levels of CAR (and PXR) mRNA in brain capillaries isolated from patient biopsies and in an immortalized human cerebral microvascular cell line (Dauchy et al., 2008).

Second, we show here that exposure of isolated brain capillaries to PB for rat and TCPOBOP for mouse, increased transport activity and protein expression of P-glycoprotein, Mrp2 and BCRP. Increases in transport activity induced in vitro averaged 80-150% over control
values, roughly equivalent to that previously reported for PXR induction of P-glycoprotein-mediated transport in rat brain capillaries (Bauer et al., 2004). PB-induced increases in transport activity were abolished when capillaries were exposed to actinomycin D or cyclohexamide, indicating dependence on transcription and translation. Consistent with involvement of CAR, increases in specific transport were abolished by the PP2A inhibitor, OA, a known modulator of CAR activity. No such increases in transport activity were seen in capillaries from CAR-null mice exposed to TCPOBOP. Capillaries from CAR-null mice were able, however, to respond to the PXR ligand, PCN, with increased transport activity of P-glycoprotein, Mrp2 and BCRP. These findings certainly implicate CAR in the upregulation of transporter protein expression in brain capillaries. However, they do not speak to the mechanism by which this happens, i.e., through direct activation of transcription by CAR binding to response elements in the promoter region of the transporter genes or indirect action through CAR-induced signaling.

Finally, dosing mice with TCPOBOP increased P-glycoprotein-, Mrp2- and BCRP-mediated transport in brain capillaries as well as protein expression of all three transporters in membranes from brain capillaries and liver (present study). Previous studies of CAR regulation of these efflux transporters in cells and tissues have focused on changes in transporter expression at the mRNA level (Burk et al., 2005; Jigorel et al., 2006; Kast et al., 2002). Thus, our results are particularly important, since they are the first to demonstrate for any tissue that in vivo exposure to a specific CAR ligand can increase ABC transporter-mediated transport as well as transporter protein expression. Note that the level of transporter induction seen here with TCPOBOP is roughly equivalent to that seen in dosing studies with PXR ligands (Bauer et al., 2006). Those latter experiments showed substantial pharmacodynamic effects of elevated P-glycoprotein expression in a transgenic mouse expressing human PXR and dosed with rifampin.
CAR ligands include endogenous bile acids, therapeutic drugs, dietary constituents and environmental pollutants (Stanley et al., 2006). All of these classes of chemicals contain substrates for transport on at least one of the ABC transporters studied here. Thus, through CAR activation, xenobiotics can induce expression of blood-brain barrier efflux pumps that limit their own access to the CNS. However, they can also induce expression of efflux transporters for which they are not substrates. Consider PB, a CAR ligand (not a PXR ligand) and an anticonvulsant that clearly enters the CNS. This drug is not a P-glycoprotein substrate and not likely to be a substrate for other drug efflux pumps. Through CAR-mediated induction, PB has the potential to increase expression of P-glycoprotein and thus selectively tighten the blood-brain barrier to many CNS-acting drugs, not including PB. Thus, as with PXR, the consequences of CAR induction of efflux transporters at the blood-brain barrier may be far-reaching. Indeed, given the promiscuity of PXR and CAR, and the use of CAR and PXR activators to treat cholestasis and jaundice (Zollner and Trauner, 2009), it is likely that a large segment of the population is already induced. One wonders about the extent to which placing patients on a diet devoid of PXR and CAR ligands might improve drug delivery to the CNS.

Although CAR and PXR were initially described as xenosensors that coordinated hepatic responses to xenobiotics, recent evidence indicates that they are also important regulators of hepatic energy metabolism. In liver, both receptors regulate expression of genes in pathways that control both lipid and carbohydrate metabolism, including genes that code for enzymes and transporters (Rezen et al., 2009). At least some of the same effects will likely be seen in non-hepatic tissues. At present, it is not clear how and to what extent CAR and PXR ligands are able to alter energy metabolism and metabolite transport at the blood-brain barrier. However, given the importance of ATP for maintenance of the selective properties of the barrier, both receptors
could indirectly alter the permeability characteristics of the endothelium to xenobiotics, nutrients, metabolites and ions.


Footnote

This research was supported by the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health.
Figure Legends

Figure 1. Constitutive active receptor (CAR) expression in the rat and mouse brain capillaries. (A) RT-PCR showed CAR expression in rat and mouse liver and brain capillaries. 1. rat liver (positive control), 2. rat brain capillaries, 3. mouse liver (positive control), 4. mouse brain capillaries, 5. negative control. (B) Western blot showing CAR protein expression in rat and mouse brain capillaries and capillary membrane fractions. (C) Immunostaining for CAR protein in freshly isolated rat brain. Representative confocal image shows CAR was distributed throughout the cytoplasm, plasma membrane and the nucleus of the endothelial cells. Left, CAR immunostaining image; right, transmitted light image. White scale bar indicates 10 μm.

Figure 2. Representative confocal images of rat brain capillaries showing luminal accumulation of fluorescent substrates specific for P-glycoprotein (A; 2 μM NBD-CSA), Mrp2 (B; 2 μM Texas Red) and BCRP (C; 2 μM BODIPY-prazosin). In each case, exposing capillaries to 1 mM PB for 3 h, prior to incubation with transport substrate increased luminal substrate accumulation. Luminal accumulation was substantially reduced when specific transport inhibitors were added to the medium (5 μM PSC833 for P-glycoprotein, 0.3 μM LTC₄ for Mrp2 and 5 μM FTC for BCRP). White scale bar indicates 10 μm.

Figure 3. Increased transport activity of P-glycoprotein (A,D), Mrp2 (B,E) and BCRP (C,F) in isolated rat brain capillaries following exposure to 1 mM PB. (A-C) Time course of PB action. Capillaries were exposed to PB for the time indicated. During the last hour of incubation 2 μM NBD-CSA (A), 2 μM Texas Red (B) or 2 μM BODIPY-prazosin (C) was present in the medium. (D-F) Effect of OA inhibition of PP2A with on PB-induced increases in transport (4 h exposure).
In both sets of experiments, capillaries treated with PSC833 (P-glycoprotein), LTC4 (Mrp2), or fumitremorgin C (FTC) or KO143 (BCRP) indicate specific inhibition of transport. Shown are mean ± SEM for 8-12 capillaries from a single preparation (pooled brains from 10 rats). Statistical comparisons: **significantly higher than control, p<0.01; significantly higher than control, ***p<0.001.

Figure 4. Upregulation of P-glycoprotein (P-gp)-, Mrp2- and BCRP-mediated transport and expression in rat brain capillaries following exposure to 1 mM PB 
\textit{in vitro}. (A-C) Increases of specific transport activity over multiple experiments (5 preparations for P-glycoprotein, 3 preparations for Mrp2 and 3 preparations for BCRP). (D) Western blots showing increased expression of all three ABC transporters in capillaries exposed to 1 mM PB for 5 h.

Figure 5. Inhibiting transcription (A,C,E; 1µM actinomycin D) or translation (B,D,F; 100µg/mL cycloheximide) blocked the effects of 1 mM PB on P-glycoprotein, Mrp2 and BCRP transport activity. Shown are mean ± SEM for 8-12 capillaries from a single preparation (pooled brains from 10 rats). Statistical comparisons: **significantly higher than control, p<0.01; significantly higher than control, ***p<0.001.

Figure 6. TCPOBOP increases transport activity in mouse brain capillaries 
\textit{in vitro}. Freshly isolated mouse brain capillaries were exposed to TCPOBOP for 4 h; during the last h, fluorescent substrates (NBD-CSA for P-glycoprotein, Texas Red for Mrp2 and BODIPY-prazosin for BCRP) and transport inhibitors were present in the medium. (A,C,E) shows concentration-dependent induction of transport with TCPOBOP. (B,D,F) shows that induction was abolished
when capillaries were pretreated for 30 min (before TCPOBOP exposure) with the PP2A inhibitor, OA. Shown are mean ± SEM for 8-12 capillaries from a single preparation (pooled brains from 10 rats). Statistical comparisons: **significantly higher than control, p<0.01; significantly higher than control, ***p<0.001.

Figure 7. TCPOBOP does not increase transport activity in brain capillaries from CAR-null mice. Protocol as in Fig. 6. (A) P-glycoprotein, (B) Mrp2, (C) BCRP. Shown are mean ± SEM for 8-12 capillaries from a single preparation (pooled brains from 10 rats). Statistical comparisons: *significantly higher than control, p<0.05; significantly higher than control, ***p<0.001.

Figure 8. Increased transport activity and expression of P-glycoprotein, Mrp2 and BCRP following exposure to CAR and PXR ligands in vivo. C3H mice were dosed by i.p. injection with 50 mg/kg PCN (PXR ligand) or 0.33 mg/kg TCPOBOP (CAR ligand) daily for 2 consecutive days. Brains and livers were collected on day 3. (A-C) Transport in freshly isolated mouse brain capillaries (1 h incubation with fluorescent substrate plus inhibitors). (A) NBD-CSA, (B) Texas Red and (C) BODIPY-prazosin. Shown are mean ± SEM for 8-12 capillaries from a single preparation (pooled brains from 10 mice). Statistical comparisons: *significantly higher than control, p<0.05; significantly higher than control, ***p<0.001. (D-F) Increases in specific transport activity of P-glycoprotein, Mrp2 and BCRP over 4-5 TCPOBOP dosing experiments.

Figure 9. Increased protein expression of P-glycoprotein, Mrp2 and BCRP following exposure to CAR ligand TCPOBOP in vivo. Western blots of P-glycoprotein (P-gp), Mrp2 and BCRP in
membranes from brain capillaries and livers of vehicle-injected (control) mice and mice dosed with the CAR ligand, TCPOBOP.

Figure 10. Increased transport activity and expression of P-glycoprotein (P-gp), Mrp2 and BCRP following exposure to the CAR activator, PB, in vivo. Rats were dosed by i.p. injection with 80 mg/kg PB daily for 4 consecutive days. Brains and livers were collected on day 5. (A-C) Transport in freshly isolated brain capillaries (1 h incubation with fluorescent substrate plus inhibitors). (A) NBD-CSA, (B) Texas Red and (C) BODIPY-prazosin. Shown are mean ± SEM for 8-12 capillaries from a single preparation (pooled brains from 10 rats). Statistical comparisons: significantly higher than control, ***p<0.001. (D) Western blots of P-glycoprotein, Mrp2 and BCRP in membranes from brain capillaries and livers of vehicle-injected (control) rats and rats dosed with the CAR activator, PB.
Fig. 4

A

B

C

D

Specific Luminal NBD-CSA Fluorescence vs. Control and PB

Specific Luminal Texas Red Fluorescence vs. Control and PB

Specific Luminal BODIPY-prazosin Fluorescence vs. Control and PB

Control and PB protein blots for P-gp, Mrp2, BCRP dimer, BCRP monomer, and β-actin.
Fig. 9

<table>
<thead>
<tr>
<th></th>
<th>Brain Capillaries</th>
<th>Liver</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>TCPOBOP</td>
</tr>
<tr>
<td>P-gp</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mrp2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCRP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The figure shows Western blot analysis for different proteins in brain capillaries and liver under control and TCPOBOP conditions.
Fig. 10

A

Luminal NBD-CSA Fluorescence

control 80mg/kg PB 5 μM PSC833

***

B

Luminal Texas Red Fluorescence

control 80mg/kg PB 10 μM MK571

***

C

Luminal BODIPY-prazosin Fluorescence

control 80mg/kg PB 1 μM KO143

***

D

Brain Capillaries

Control | PB
--------|--------
P-gp     | ![Image](image)
Mrp2    | ![Image](image)
BCRP dimer | ![Image](image)
BCRP monomer | ![Image](image)
β-actin | ![Image](image)

Liver

Control | PB
--------|--------
P-gp     | ![Image](image)
Mrp2    | ![Image](image)
BCRP    | ![Image](image)
Cyp2b1/2b2 | ![Image](image)
β-actin | ![Image](image)